Graybug Vision Begins Phase I/II Trial for Candidate in Wet AMD

September 22, 2017: By Jon Swedien

GraybugGraybug Vision has begun dosing patients in a Phase I/II clinical trial for GB-102, its lead product candidate for wet age-related macular degeneration (AMD), the Redwood City, California, company announced Sept. 19.

GB-102 is a novel intravitreal (IVT) injectable depot formulation of sunitinib malate, a tyrosine kinase inhibitor that blocks multiple angiogenesis pathways. GB-102 has the potential to be a twice annual treatment for wet AMD, Graybug said.

The two-part study—ADAGIO—will evaluate wet AMD patients currently being treated with available IVT anti-VEGF agents who are then switched over to treatment with GB-102 alone, Graybug said.

Part one is a multicenter, open-label, single IVT injection study of up to four dose levels of GB-102 administered in ascending dosing cohorts, Graybug said. Following the single IVT injection of GB-102, patients will undergo monthly evaluation for eight months to assess safety, tolerability, and functional/pharmacodynamic parameters, including visual acuity and optical coherence tomography (OCT) measures of the retina, Graybug said.

Part two is a multicenter, double-masked, randomized, parallel-group, safety, and efficacy evaluation of repeated IVT injections of two dose levels of GB-102 compared with a standard IVT regimen of aflibercept, Graybug said.

Graybug said it also has a second-generation product under development, GB-103, that has potential to be a once-per-year IVT treatment for wet AMD.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Eylea Gains Approval in China for DME-Related Visual Impairment

Second Trial for Ophthalmic Industry Leader James Mazzo Ends in Hung Jury, Mistrial

Melgen Receives 17-Year Sentence for Medicare Fraud

NIH’s National Eye Institute Solicits Next-Generation Retina Organoids in $1 Million Prize Competition

Taiwan Liposome Company Registers for $50 Million IPO in US

US FDA Approves Icon Bioscience’s DEXYCU for Post-Cataract Surgery Inflammation

FDA’s Gottlieb Appears to Soften Stance on Compounding for Office Use

Genentech’s RG7716 Outperformed Ranibizumab in Phase II Study in Diabetic Macular Edema

Santen Reports Promising Data in Phase I/II Study in Refractory Wet AMD

Q Biomed Signs Agreement with Washington University for Novel Biomarker for Monitoring Glaucoma

pSivida’s Durasert for Posterior Segment Uveitis Yields Positive 12-Month Results in Second Phase III Study

Foundation Fighting Blindness Provides $7.5 Million to Help Develop ProQR’s Candidate for Usher Syndrome

Presbia Names Casey Lind as Chief Operating Officer, Magda Michna, MD, PhD, as Chief Clinical Officer

Astellas Acquires Universal Cells

Pixium Vision Completes Two Successful PRIMA Implantations in Atrophic Dry AMD Patients

Omeros Loses Pass-through Status for Omidria

USC Donations Drop $100 Million after Puliafito Scandal, Report Says

Regeneron’s US Eylea Sales Increase 14 Percent in Q4-2017

Allergan’s Net Sales Climb 12 Percent in Q4-2017; Restasis Sales Grow Nearly 1 Percent

Lucentis’ US Sales Drop 11 percent in Q4-2017, Grow 1 Percent for Full 2017

Coming soon

2018 Retinal Surgical Devices Report: A Global Market Analysis for 2017 to 2023